Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
Forecast Insight - Parkinson's Disease - Market upgrade following evidence of disease slowing with Azilect (Datamonitor)
- Market: Healthcare and Medical
- Published Date: 08/09/2008
- Report Title: Forecast Insight - Parkinson's Disease - Market upgrade following evidence of disease slowing with Azilect
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 123
Introduction
Stimulated by evidence of disease slowing with Teva/Lundbeck's Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson's disease market value is set to grow by an compound annual growth rate (CAGR) of 10% over the next 5 years (20072013), peaking at $3.1 billion in 2013.
Scope
*This report gives a strategic analysis of the likely impact that recent events will have on the future Parkinson's disease market
*Includes Parkinson's disease-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017
*Provides a global market snapshot by including Parkinson's disease-specific sales analysis for leading brands outside the seven major markets
*Key conclusions are supported by key opinion leader comment
Highlights
Datamonitor has upgraded its forecasts of Teva/Lundbeck's Azilect (rasagiline) following clinical evidence of disease slowing. Over the next 5 years Azilect is expected to become a standard first-line therapy, with sales peaking in 2013, making it the market leading Parkinson's disease drug at this time.
GlaxoSmithKline's Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing, supported by the theoretical clinical advantage of smoother dopamine receptor agonism, will drive switching from the parent compound and Boehringer Ingelheim's Mirapex (pramipexole).
Datamonitor has downgraded its sales forecasts of UCB's Neupro (rotigotine patch) as problems with crystallization of the active ingredient have led to supply issues at a critical phase in its lifecycle. Prescribers are now likely to switch to Requip XL, which arrived on the market at just the right time to take advantage of UCB's misfortune.
Reasons to Purchase
*Understand the impact of recent and anticipated events on the Parkinson's disease market during the forecast period 2008 to 2017
*Quantify the current size of the seven major markets and the trends in the rest of the world
*Assess the impact of events, such as patent expiries and new product launches, on the Parkinson's disease-specific sales of key brands
Stimulated by evidence of disease slowing with Teva/Lundbeck's Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson's disease market value is set to grow by an compound annual growth rate (CAGR) of 10% over the next 5 years (20072013), peaking at $3.1 billion in 2013.
Scope
*This report gives a strategic analysis of the likely impact that recent events will have on the future Parkinson's disease market
*Includes Parkinson's disease-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017
*Provides a global market snapshot by including Parkinson's disease-specific sales analysis for leading brands outside the seven major markets
*Key conclusions are supported by key opinion leader comment
Highlights
Datamonitor has upgraded its forecasts of Teva/Lundbeck's Azilect (rasagiline) following clinical evidence of disease slowing. Over the next 5 years Azilect is expected to become a standard first-line therapy, with sales peaking in 2013, making it the market leading Parkinson's disease drug at this time.
GlaxoSmithKline's Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing, supported by the theoretical clinical advantage of smoother dopamine receptor agonism, will drive switching from the parent compound and Boehringer Ingelheim's Mirapex (pramipexole).
Datamonitor has downgraded its sales forecasts of UCB's Neupro (rotigotine patch) as problems with crystallization of the active ingredient have led to supply issues at a critical phase in its lifecycle. Prescribers are now likely to switch to Requip XL, which arrived on the market at just the right time to take advantage of UCB's misfortune.
Reasons to Purchase
*Understand the impact of recent and anticipated events on the Parkinson's disease market during the forecast period 2008 to 2017
*Quantify the current size of the seven major markets and the trends in the rest of the world
*Assess the impact of events, such as patent expiries and new product launches, on the Parkinson's disease-specific sales of key brands
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card ; Credit Card ; Purchase via Invoice (inc. Purchase Order no. if required) and Paypal. Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
